Cargando…
Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities. We evaluated the efficacy of mecillinam in combination with either avibactam or ceftazidime/avibactam agains...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599007/ https://www.ncbi.nlm.nih.gov/pubmed/36289937 http://dx.doi.org/10.3390/antibiotics11101280 |
_version_ | 1784816488778039296 |
---|---|
author | List, Karoline Knudsen Kolpen, Mette Kragh, Kasper Nørskov Charbon, Godefroid Radmer, Stine Hansen, Frank Løbner-Olesen, Anders Frimodt-Møller, Niels Hertz, Frederik Boetius |
author_facet | List, Karoline Knudsen Kolpen, Mette Kragh, Kasper Nørskov Charbon, Godefroid Radmer, Stine Hansen, Frank Løbner-Olesen, Anders Frimodt-Møller, Niels Hertz, Frederik Boetius |
author_sort | List, Karoline Knudsen |
collection | PubMed |
description | Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities. We evaluated the efficacy of mecillinam in combination with either avibactam or ceftazidime/avibactam against carbapenemase-producing clinical isolates. Materials and methods: Nineteen MDR clinical isolates of K. pneumoniae and E. coli were selected for the presence of blaKPC, blaNDM, blaOXA or blaIMP based on whole-genome sequencing and phenotypic susceptibility testing. We tested the synergy between mecillinam and avibactam or ceftazidime/avibactam. We used time–kill studies in vitro and a mouse peritonitis/sepsis model to confirm the synergistic effect. We investigated avibactam’s impact on mecillinam´s affinity for penicillin-binding proteins with a Bocillin assay, and cell changes with phase-contrast and confocal laser scanning microscopy. Results: Mecillinam combined with ceftazidime/avibactam or avibactam substantially reduced MICs (from up to >256 µg/mL to <0.0016 µg/mL) for 17/18 strains. Significant log-CFU reductions were confirmed in time–kill and in vivo experiments. The Bocillin assay did not reveal changes. Conclusion: Mecillinam in combination with avibactam or ceftazidime/avibactam has a notable effect on most types of CPEs, both in vitro and in vivo. The mecillinam/avibactam combination treatment could be a new efficient antibiotic treatment against multi-drug-resistant carbapenemase-producing Gram-negative pathogens. |
format | Online Article Text |
id | pubmed-9599007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95990072022-10-27 Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae List, Karoline Knudsen Kolpen, Mette Kragh, Kasper Nørskov Charbon, Godefroid Radmer, Stine Hansen, Frank Løbner-Olesen, Anders Frimodt-Møller, Niels Hertz, Frederik Boetius Antibiotics (Basel) Article Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities. We evaluated the efficacy of mecillinam in combination with either avibactam or ceftazidime/avibactam against carbapenemase-producing clinical isolates. Materials and methods: Nineteen MDR clinical isolates of K. pneumoniae and E. coli were selected for the presence of blaKPC, blaNDM, blaOXA or blaIMP based on whole-genome sequencing and phenotypic susceptibility testing. We tested the synergy between mecillinam and avibactam or ceftazidime/avibactam. We used time–kill studies in vitro and a mouse peritonitis/sepsis model to confirm the synergistic effect. We investigated avibactam’s impact on mecillinam´s affinity for penicillin-binding proteins with a Bocillin assay, and cell changes with phase-contrast and confocal laser scanning microscopy. Results: Mecillinam combined with ceftazidime/avibactam or avibactam substantially reduced MICs (from up to >256 µg/mL to <0.0016 µg/mL) for 17/18 strains. Significant log-CFU reductions were confirmed in time–kill and in vivo experiments. The Bocillin assay did not reveal changes. Conclusion: Mecillinam in combination with avibactam or ceftazidime/avibactam has a notable effect on most types of CPEs, both in vitro and in vivo. The mecillinam/avibactam combination treatment could be a new efficient antibiotic treatment against multi-drug-resistant carbapenemase-producing Gram-negative pathogens. MDPI 2022-09-20 /pmc/articles/PMC9599007/ /pubmed/36289937 http://dx.doi.org/10.3390/antibiotics11101280 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article List, Karoline Knudsen Kolpen, Mette Kragh, Kasper Nørskov Charbon, Godefroid Radmer, Stine Hansen, Frank Løbner-Olesen, Anders Frimodt-Møller, Niels Hertz, Frederik Boetius Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae |
title | Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae |
title_full | Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae |
title_fullStr | Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae |
title_full_unstemmed | Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae |
title_short | Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae |
title_sort | synergy between mecillinam and ceftazidime/avibactam or avibactam against multi-drug-resistant carbapenemase-producing escherichia coli and klebsiella pneumoniae |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599007/ https://www.ncbi.nlm.nih.gov/pubmed/36289937 http://dx.doi.org/10.3390/antibiotics11101280 |
work_keys_str_mv | AT listkarolineknudsen synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT kolpenmette synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT kraghkaspernørskov synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT charbongodefroid synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT radmerstine synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT hansenfrank synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT løbnerolesenanders synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT frimodtmøllerniels synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae AT hertzfrederikboetius synergybetweenmecillinamandceftazidimeavibactamoravibactamagainstmultidrugresistantcarbapenemaseproducingescherichiacoliandklebsiellapneumoniae |